Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Study of teriflunomide in reducing the frequency of relapses and accumulation of disability in patients with multiple sclerosis (TEMSO)
Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories.
3 Blockbuster Drugs Losing Patent Protection in 2013's Final Months
Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy.
Use of amiloride and multiple sclerosis: registry-based cohort studies.
Beginning of the end of two-stage theory purporting that inflammation then degeneration explains pathogenesis of progressive multiple sclerosis.
Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.
Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS.
Rapid exacerbation of neuromyelitis optica after rituximab treatment.
LC-MS/MS determination of FTY720 and FTY720-phosphate in murine intracellular compartments and human plasma.
Effects of 2-Chlorodeoxyadenosine (Cladribine) on Primary Rat Microglia.
Receptos to initiate Phase 3 trial of RPC1063 in relapsing multiple sclerosis
Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review.
Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.
Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.
Rituximab and multiple sclerosis.
Opinion: Sex inclusion in basic research drives discovery.
FDA approval announcement for ofatumumab
Charcot-Marie-Tooth 1A: a narrative review with clinical and anatomical perspectives.
Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study.
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Gene expression analysis reveals functional pathways of glatiramer acetate activation.
Biogen Idec submits application to FDA for approval of PLEGRIDY™ (peginterferon beta-1a) in multiple sclerosis
Myelin-specific Th17 cells induce severe relapsing optic neuritis with irreversible loss of retinal ganglion cells in C57BL/6 mice.

Pages